Atenolol vs Carvedilol
## Overview
Atenolol and carvedilol represent two distinct generations of beta-blocker therapy. Atenolol is a first-generation cardioselective beta-blocker with limited outcome evidence beyond blood pressure reduction. Carvedilol is a third-generation non-selective beta-blocker with alpha-1 blockade and proven mortality benefit in HFrEF.
## Mechanism of Action
Atenolol: cardioselective beta-1 antagonist, hydrophilic. Carvedilol: non-selective beta-1/beta-2 + alpha-1 + antioxidant.
## Clinical Evidence
Carvedilol has robust evidence from multiple HFrEF trials (US Carvedilol Trials, COPERNICUS, CAPRICORN). Atenolol's ASCOT-BPLA trial showed it was inferior to a calcium channel blocker-based regimen for cardiovascular prevention, reducing its standing as a preferred antihypertensive.
## Metabolic Effects
Atenolol is associated with greater metabolic adverse effects (increased triglycerides, impaired glycemic control) compared to carvedilol, which has been shown to have neutral or beneficial metabolic effects in HF patients with diabetes.
## Key Takeaways
- Carvedilol is the superior agent for HFrEF (Class I recommendation)
- Atenolol: no HF evidence, questioned for hypertension monotherapy
- Carvedilol's alpha-1 blockade provides vasodilation; more first-dose hypotension
บทสรุป
Carvedilol is strongly preferred over atenolol for heart failure management. For hypertension, carvedilol is more evidence-based. Atenolol should not be used for HFrEF and its role in uncomplicated hypertension management has diminished in contemporary guidelines.